Could a simple change in insulin timing improve pregnancy outcomes for women with diabetes?

NCT ID NCT07224893

First seen Nov 05, 2025 · Last updated Jun 23, 2026 · Updated 28 times

Summary

This study compares taking insulin glargine once a day versus twice a day in pregnant women with pregestational diabetes (type 2 diabetes that existed before pregnancy). About 200 participants will be randomly assigned to one of the two groups, and their blood sugar levels will be tracked continuously. The goal is to see if twice-daily dosing leads to better blood sugar control and fewer pregnancy complications like preterm birth or high blood pressure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Sentara Norfolk General Hospital, Norfolk, Virginia 23507

    RECRUITING

    Norfolk, Virginia, 23507, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

insulin glargine

What this could lead to

If successful, this could show that a simple change in dosing schedule helps pregnant women with diabetes achieve better blood sugar control, potentially reducing pregnancy complications.

What could go wrong

This is a small, early-phase study (200 participants) comparing two common dosing schedules, so the difference may be small or not clinically meaningful. Results may not apply to all types of diabetes or pregnancies.

Conditions

The condition(s) this trial relates to.

gestational diabetes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.